Cargando…

Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta‐analysis

AIMS: We sought to conduct a meta‐analysis regarding the safety and efficacy of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors in patients with heart failure (HF). METHODS AND RESULTS: MEDLINE, Scopus, Cochrane CENTRAL, and ClinicalTrials.gov were searched from their inception to November 2020 f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Butler, Javed, Usman, Muhammad Shariq, Khan, Muhammad Shahzeb, Greene, Stephen J., Friede, Tim, Vaduganathan, Muthiah, Filippatos, Gerasimos, Coats, Andrew J. Stewart, Anker, Stefan D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755023/ https://www.ncbi.nlm.nih.gov/pubmed/33586910 http://dx.doi.org/10.1002/ehf2.13169

Ejemplares similares

Robustness of outcomes in trials evaluating sodium–glucose co‐transporter 2 inhibitors for heart failure
por: Usman, Muhammad Shariq, et al.
Publicado: (2022)

Reporting and interpretation of subgroup analyses in heart failure randomized controlled trials
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2020)

What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2020)

Ferric carboxymaltose for the treatment of iron‐deficient heart failure patients: a systematic review and meta‐analysis
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2020)

Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency
por: Butler, Javed, et al.
Publicado: (2022)

Effect of Carillon Mitral Contour System on patient‐reported outcomes in functional mitral regurgitation: an individual participant data meta‐analysis
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2021)

Discontinuation and non‐publication of heart failure randomized controlled trials: a call to publish all trial results
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2020)

Responder analysis for improvement in 6‐min walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency
por: Anker, Stefan D., et al.
Publicado: (2022)

Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure
por: Packer, Milton, et al.
Publicado: (2023)

Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction
por: Tomasoni, Daniela, et al.
Publicado: (2022)

Recognizing the Significance of Outpatient Worsening Heart Failure
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2020)

Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR‐Reduced
por: Anker, Stefan D., et al.
Publicado: (2022)

Renin–angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta‐analysis
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2017)

SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence
por: Talha, Khawaja M., et al.
Publicado: (2023)

Targeting Mitochondrial Function in Heart Failure: Makes Sense But Will it Work?
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2019)

Reductions in Heart Failure Hospitalizations During the COVID-19 Pandemic
por: HALL, MICHAEL E., et al.
Publicado: (2020)

Frailty and heart failure: State‐of‐the‐art review
por: Talha, Khawaja M., et al.
Publicado: (2023)

Totality of evidence in trials of sodium–glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice
por: Butler, Javed, et al.
Publicado: (2020)

Sodium–Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2019)

Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction: A Post Hoc Analysis of the EMPEROR-Preserved Trial
por: Butler, Javed, et al.
Publicado: (2023)

Trends and characteristics of hospitalizations for heart failure in the United States from 2004 to 2018
por: Salah, Husam M., et al.
Publicado: (2022)

Functional outcomes with Carillon device over 1 year in patients with functional mitral regurgitation of Grades 2+ to 4+: results from the REDUCE‐FMR trial
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2021)

Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2022)

Application of the Reverse Fragility Index to Statistically Nonsignificant Randomized Clinical Trial Results
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2020)

Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial
por: Butler, Javed, et al.
Publicado: (2021)

Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction
por: Butler, Javed, et al.
Publicado: (2021)

Empagliflozin, calcium, and SGLT1/2 receptor affinity: another piece of the puzzle
por: Anker, Stefan D., et al.
Publicado: (2018)

Clinical effects of cardiac contractility modulation in heart failure with mildly reduced systolic function
por: Tschöpe, Carsten, et al.
Publicado: (2020)

Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure: A Secondary Analysis of EMPEROR-Pooled
por: Ferreira, João Pedro, et al.
Publicado: (2022)

Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR‐Reduced
por: Ferreira, João Pedro, et al.
Publicado: (2022)

Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial
por: Butler, Javed, et al.
Publicado: (2021)

Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER‐like endpoint definitions
por: Anker, Stefan D., et al.
Publicado: (2022)

Design of a prospective patient‐level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure
por: Packer, Milton, et al.
Publicado: (2020)

A rationale for dedicated trials of combination therapy in heart failure
por: Blumer, Vanessa, et al.
Publicado: (2022)

Out-of-Pocket Costs for SGLT-2 (Sodium-Glucose Transport Protein-2) Inhibitors in the United States
por: Aggarwal, Rahul, et al.
Publicado: (2021)

Dronedarone for the treatment of atrial fibrillation with concomitant heart failure with preserved and mildly reduced ejection fraction: a post‐hoc analysis of the ATHENA trial
por: Vaduganathan, Muthiah, et al.
Publicado: (2022)

Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme
por: Zannad, Faiez, et al.
Publicado: (2022)

Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies
por: Anker, Stefan D., et al.
Publicado: (2015)

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial
por: Anker, Stefan D., et al.
Publicado: (2020)

A Meta-analysis of the Relationship Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19
por: Usman, Muhammad Shariq, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_d615ii5nkjk8u7tscuu1i3avcj